---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-007344"
form_type: "8-K"
ticker: "AGPU"
cik: "0001446159"
company_name: "Axe Compute Inc."
filed_at: "2025-11-14T23:59:59+00:00"
generated_at: "2026-05-16T19:49:57.773116+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Predictive Oncology Q3 EPS loss $(107.24); records $74.4M derivative liability on ATH token strategy

## Summary
- Revenue of $3,618 virtually unchanged from $3,907 in Q3 2024; cash fell to $181,667 from $611,822 at Dec 31, 2024.
- GAAP net loss per share from continuing operations of $(107.24), including a $74.4M loss on derivative instruments.
- Held 5.70 billion ATH tokens as of Nov 10, 2025; market value ~$152.8M, with 3.7B locked and 2.0B unlocked.
- Received ~$50.8M cash proceeds and ~$292.7M in-kind ATH notional from two private placements under new digital asset treasury strategy.
- Appointed Shawn Matthews (former CEO of Cantor Fitzgerald) to Board of Directors; strategic collaboration with Every Cure announced.

## SEC filing metadata
- accession: 0001171843-25-007344
- form_type: 8-K
- ticker: AGPU
- cik: 0001446159
- company_name: Axe Compute Inc.
- filed_at: 2025-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1446159/000117184325007344/0001171843-25-007344-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1446159/000117184325007344/f8k_111425.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-007344
- JSON: https://secwatch.observer/filing/0001171843-25-007344.json
- Plain text: https://secwatch.observer/filing/0001171843-25-007344.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.